Structure, function and inhibition of Bcl-2 family proteins: A new target for anti-tumor agents

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 14, 2009, Pages 1596-1604

  Xiao, Guizhi ^a   Fang, Hao ^a   Xing, Chengguo ^b   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anti tumor; Apoptosis; Bcl 2; Function; Inhibitors; Structure

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCL2 RELATED PROTEIN A1; BH3 PROTEIN; BH3I 1; BH3I 2; BIM PROTEIN; CHELERYTHRINE; CPM 1285; GOSSYPOL; OBATOCLAX; OBLIMERSEN; OGX 011; POLYPHENOL DERIVATIVE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL X; PROTEIN BCL XL; PROTEIN BID; PROTEIN BMF; PROTEIN BOK; PROTEIN MCL 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; CELL FATE; CLINICAL TRIAL; HUMAN; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 77949888700     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709791012238     Document Type: Review

References (75)

1. Zimmermann, K. C.; Bonzon, C.; Green, D. R. The machinery of programmed cell death. Pharmacol. Ther., 2001, 92, 57-70.
2. Hachem, A.; Gartenhaus, R. B. Oncogenes as molecular targets in lymphoma. Blood, 2005, 106, 1911-1923.
3. Letai, A.; Sorcinelli, M. D.; Beard, C.; Korsmeyer, S. J. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell, 2004, 6, 241-9.
4. Riedl, S. J.; Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol., 2004, 5, 897-907.
5. Sanchez-Beato, M.; Sanchez-Aguilera, A.; Piris, M. A. Cell cycle deregulation in B-cell lymphomas. Blood, 2003, 101, 1220-35.
6. Droin, N. M.; Green, D. R. Role of Bcl-2 family members in immunity and disease. Biochim. Biophys. Acta, Mol. Cell Res., 2004, 1644, 179-188.
7. Huang, Z. W. The chemical biology of apoptosis: Exploring protein-protein interactions and the life and death of cells with small molecules.Chem. Biol., 2002, 9, 1059-1072.
8. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol., 2008, 9, 47-59.
9. Hinds, M. G.; Day, C. L. Regulation of apoptosis: uncovering the binding determinants. Curr. Opin. Struct. Biol., 2005, 15, 690-9.
10. Antonsson, B.; Martinou, J. C. The Bcl-2 protein family. Exp. Cell Res., 2000, 256, 50-7.
11. Wang, K.; Gross, A.; Waksman, G.; Korsmeyer, S. J. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol. Cell Biol., 1998, 18, 6083-9.
12. Muchmore, S. W.; Sattler, M.; Liang, H.; Meadows, R. P.; Harlan, J. E.; Yoon, H. S.; Nettesheim, D.; Chang, B. S.; Thompson, C. B.; Wong, S. L.; Ng, S. L.; Fesik, S. W. X-ray and NMR structure of human Bcl-x(L), an inhibitor of programmed cell death. Nature, 1996, 381, 335-41.
13. Kelekar, A.; Thompson, C. B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol., 1998, 8, 324-30.
14. Shimizu, S.; Konishi, A.; Kodama, T.; Tsujimoto, Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 3100-5.
15. Fleischer, A.; Ghadiri, A.; Dessauge, F.; Duhamel, M.; Rebollo, M. P.; Alvarez-Franco, F.; Rebollo, A. Modulating apoptosis as a target for effective therapy. Mol. Immunol., 2006, 43, 1065-1079.
16. Wolter, K. G.; Hsu, Y. T.; Smith, C. L.; Nechushtan, A.; Xi, X. G.; Youle, R. J. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol., 1997, 139, 1281-92.
17. Liang, H.; Fesik, S. W. Three-dimensional structures of proteins involved in programmed cell death. J. Mol. Biol., 1997, 274, 291-302.
18. Chang, B. S.; Minn, A. J.; Muchmore, S. W.; Fesik, S. W.; Thompson, C. B. Identification of a novel regulatory domain in Bcl-x(L) and Bcl-2. EMBO J., 1997, 16, 968-77.
19. Petros, A. M.; Medek, A.; Nettesheim, D. G.; Kim, D. H.; Yoon, H. S.; Swift, K.; Matayoshi, E. D.; Oltersdorf, T.; Fesik, S. W. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 3012-7.
20. Denisov, A. Y.; Madiraju, M. S.; Chen, G.; Khadir, A.; Beauparlant, P.; Attardo, G.; Shore, G. C.; Gehring, K. Solution structure of human BCL-w - Modulation of ligand binding by the C-terminal helix. J. Biol. Chem., 2003, 278, 21124-8.
21. McDonnell, J. M.; Fushman, D.; Milliman, C. L.; Korsmeyer, S. J.; Cowburn, D. Solution structure of the proapoptotic molecule BID: A structural basis for apoptotic agonists and antagonists. Cell, 1999, 96, 625-34.
22. Chou, J. J.; Li, H.; Salvesen, G. S.; Yuan, J.; Wagner, G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell, 1999, 96, 615-24.
23. Suzuki, M.; Youle, R. J.; Tjandra, N. Structure of Bax: Coregulation of dimer formation and intracellular localization. Cell, 2000, 103, 645-54.
24. Tjandra, N.; Bax, A. Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium. Science, 1997, 278, 1111-4.
25. Oltvai, Z. N.; Milliman, C. L.; Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 1993, 74, 609-19.
26. Oakes, S. A.; Opferman, J. T.; Pozzan, T.; Korsmeyer, S. J.; Scorrano, L. Regulation of endoplasmic reticulum Ca2+ dynamics by proapoptotic BCL-2 family members. Biochem. Pharmacol., 2003, 66, 1335-40.
27. Degterev, A.; Boyce, M.; Yuan, J. The channel of death. J. Cell Biol., 2001, 155, 695-8.
28. Kuwana, T.; Mackey, M. R.; Perkins, G.; Ellisman, M. H.; Latterich, M.; Schneiter, R.; Green, D. R.; Newmeyer, D. D. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell, 2002, 111, 331-42.
29. Martinou, J. C.; Desagher, S.; Antonsson, B. Cytochrome c release from mitochondria: all or nothing. Nat. Cell Biol., 2000, 2, E41-3.
30. Scorrano, L.; Oakes, S. A.; Opferman, J. T.; Cheng, E. H.; Sorcinelli, M. D.; Pozzan, T.; Korsmeyer, S. J. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science, 2003, 300, 135-9.
31. Chittenden, T. BH3 domains: intracellular death-ligands critical for initiating apoptosis. Cancer Cell, 2002, 2, 165-6.
32. Kelekar, A.; Chang, B. S.; Harlan, J. E.; Fesik, S. W.; Thompson, C. B. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-x(L). Mol. Cell. Biol., 1997, 17, 7040-7046.
33. Letai, A. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest., 2005, 115, 2648-55.
34. Adams, J. M.; Cory, S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol., 2007, 19, 488-96.
35. van Delft, M. F.; Huang, D. C. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res., 2006, 16, 203-13.
36. Skommer, J.; Wlodkowic, D.; Deptala, A. Larger than life: Mitochondria and the Bcl-2 family. Leuk. Res, 2007, 31, 277-86.
37. Marzo, I.; Naval, J. Bcl-2 family members as molecular targets in cancer therapy. Biochem. Pharmacol., 2008, 76, 939-46.
38. Zangemeister-Wittke, U.; Leech, S. H.; Olie, R. A.; Simoes-Wust, A. P.; Gautschi, O.; Luedke, G. H.; Natt, F.; Haner, R.; Martin, P.; Hall, J.; Nalin, C. M.; Stahel, R. A. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res., 2000, 6, 2547-55.
39. Webb, A.; Cunningham, D.; Cotter, F.; Clarke, P. A.; di Stefano, F.; Ross, P.; Corbo, M.; Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 1997, 349, 1137-41.
40. Wacheck, V.; Cejka, D.; Sieghart, W.; Losert, D.; Strommer, S.; Crevenna, R.; Monia, B. P.; Selzer, E. Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol. Ther., 2006, 5, 1348-54.
41. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Bociek, R. G.; Pavletic, S.; Rai, K. R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 25, 1114-20.
42. Letai, A.; Bassik, M. C.; Walensky, L. D.; Sorcinelli, M. D.; Weiler, S.; Korsmeyer, S. J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2002, 2, 183-92.
43. Wang, J. L.; Zhang, Z. J.; Choksi, S.; Shan, S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Korngold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res., 2000, 60, 1498-502.
44. Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X. L.; Zanze, I.; Zhang, H. C.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-x(L) from NMR and parallel synthesis. J. Med. Chem., 2006, 49, 656-663.
45. Park, C.-M.; Oie, T.; Petros, A. M.; Zhang, H.; Nimmer, P. M.; Henry, R. F.; Elmore, S. W. Design, synthesis, and computational studies of inhibitors of Bcl-X-L. J. Am. Chem. Soc.,2006, 128, 16206-16212.
46. O'Neill, J.; Manion, M.; Schwartz, P.; Hockenbery, D. M. Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim. Biophys. Acta Rev. Cancer, 2004, 1705, 43-51.
47. Wang, J. L.; Liu, D.; Zhang, Z. J.; Shan, S.; Han, X.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 7124-9.
48. Zimmermann, A. K.; Loucks, F. A.; Le, S. S.; Butts, B. D.; Florez-McClure, M. L.; Bouchard, R. J.; Heidenreich, K. A.; Linseman, D. A. Distinct mechanisms of neuronal apoptosis are triggered by antagonism of Bcl-2/Bcl-x(L) versus induction of the BH3-only protein Bim. J. Neurochem., 2005, 94, 22-36.
49. Manero, F.; Gautier, F.; Gallenne, T.; Cauquil, N.; Gree, D.; Cartron, P. F.; Geneste, O.; Gree, R.; Vallette, F. M.; Juin, P. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res., 2006, 66, 2757-64.
50. Juin, P.; Geneste, O.; Raimbaud, E.; Hickman, J. A. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim. Biophys. Acta, 2004, 1644, 251-260.
51. Skommer, J.; Wlodkowic, D.; Matto, M.; Eray, M.; Pelkonen, J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk. Res., 2006, 30, 322-331.
52. Doshi, J. M.; Tian, D. F.; Xing, C. G. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3- carboxylat e (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J. Med . Chem., 2006, 49, 7731-7739.
53. Tian, D. F.; Das, S. G.; Doshi, J. M.; Peng, J.; Lin, H. L.; Xing, C. G. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett., 2008, 259, 198-208.
54. Qiu, J.; Levin, L. R.; Buck, J.; Reidenberg, M. M. Different pathways of cell killing by gossypol enantiomers. Exp. Biol. Med. (Maywood), 2002, 227, 398-401.
55. Le Blanc, M.; Russo, J.; Kudelka, A. P.; Smith, J. A. An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol. Res, 2002, 46, 551-5.
56. Oliver, C. L.; Miranda, M. B.; Shangary, S.; Land, S.; Wang, S.; Johnson, D. E. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol. Cancer Ther., 2005, 4, 23-31.
57. Becattini, B.; Kitada, S.; Leone, M.; Monosov, E.; Chandler, S.; Zhai, D.; Kipps, T. J.; Reed, J. C.; Pellecchia, M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X-L. Chem. Biol, 2004, 11, 389-95.
58. Wang, G.; Nikolovska-Coleska, Z.; Yang, C.-Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; Meagher, J.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P. P.; Abaan, H. O.; Tomita, Y.; Wang, S. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem., 2006, 49, 6139-6142.
59. Tang, G.; Yang, C.-Y.; Nikolovska-Coleska, Z.; Guo, J.; Qiu, S.; Wang, R.; Gao, W.; Wang, G.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P. P.; Wang, S. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. J. Med. Chem., 2007, 50, 1723-1726.
60. Tang, G.; Nikolovska-Coleska, Z.; Qiu, S.; Yang, C.-Y.; Guo, J.; Wang, S. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. J. Med. Chem., 2008, 51, 717-720.
61. Verhaegen, M.; Bauer, J. A.; de la Vega, C. M.; Wang, G.; Wolter, K. G.; Brenner, J. C.; Nikolovska-Coleska, Z.; Bengtson, A.; Nair, R.; Elder, J. T.; Van Brocklin, M.; Carey, T. E.; Bradford, C. R.; Wang, S.; Soengas, M. S. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res., 2006, 66, 11348-11359.
62. Mohammad, R. M.; Goustin, A. S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin. Cancer Res., 2007, 13, 2226-35.
63. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (London) , 2005, 435, 677-681.
64. Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; Anderson, K. C. A novel Bcl-2/Bcl-X-L/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene, 2007, 26, 2374-80.
65. Trudel, S.; Stewart, A. K.; Li, Z.; Shu, Y.; Liang, S. B.; Trieu, Y.; Reece, D.; Paterson, J.; Wang, D.; Wen, X. Y. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin. Cancer Res, 2007, 13, 621-9.
66. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10, 389-99.
67. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins. J. Med. Chem., 2008, 51, 6902-15.
68. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. Y. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-x(L). Nat. Cell Biol., 2001, 3, 173-182.
69. Chan, S. L.; Lee, M. C.; Tan, K. O.; Yang, L. K.; Lee, A. S. Y.; Flotow, H.; Fu, N. Y.; Butler, M. S.; Soejarto, D. D.; Buss, A. D.; Yu, V. C. Identification of chelerythrine as an inhibitor of BclXL function. J. Biol. Chem., 2003, 278, 20453-20456.
70. Zhang, Y.-H.; Bhunia, A.; Wan, K. F.; Lee, M. C.; Chan, S.-L.; Yu, V. C. K.; Mok, Y.-K. Chelerythrine and sanguinarine dock at distinct sites on Bcl(XL) that are not the classic BH3 binding cleft. J. Mol. Biol., 2006, 364, 536-549.
71. Trudel, S.; Li, Z. H.; Rauw, J.; Tiedemann, R. E.; Wen, X. Y.; Stewart, A. K. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood, 2007, 109, 5430-8.
72. Shore, G. C.; Viallet, J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology Am. Soc. Hematol. Educ. Program, 2005, 226-30.
73. Li, jn; Viallet, J; Haura ,E.B. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol., 2008, 61, 525-534
74. Arkin, M. Protein-protein interactions and cancer: small molecules going in for the kill. Curr. Opin. Chem. Biol., 2005, 9, 317-324.
75. Baell, J. B.; Huang, D. C. S. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol., 2002, 64, 851-863.